HPV16 RNA patterns defined by novel high-throughput RT-qPCR as triage marker in HPV-based cervical cancer precursor screening

Gynecologic Oncology

Volumn 138, Issue 3, 2015, Pages 676-682

  Höfler, Daniela ^a   Böhmer, Gerd ^b,c   Von Wasielewski, Reinhard ^b,d   Neumann, Heinrich ^b,e   Halec, Gordana ^a,f   Holzinger, Dana ^a   Dondog, Bolormaa ^a   Gissmann, Lutz ^a   Pawlita, Michael ^a   Schmitt, Markus ^a,g  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Zentrum für IVF und Reproduktionsmedizin   (Germany)

^c IZD Hannover   (Germany)

^d Klinikum Hannover   (Germany)

^e Gemeinschaftspraxis für Pathologie ^*  (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g GATC Biotech AG   (Germany)

Author keywords

Cervical intraepithelial neoplasia; E1 E4; E1C; E6; HPV16 RNA patterns; I; Triage test

Indexed keywords

BUFFER; CELL DNA; TUMOR MARKER; UBIQUITIN C; VIRUS DNA; VIRUS RNA;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER SCREENING; CELL COUNT; CELL ISOLATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC TRANSFORMATION; GENOTYPE; HIGH THROUGHPUT SCREENING; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; OBSTETRIC PATIENT; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA DEGRADATION; RNA EXTRACTION; TUMOR INVASION; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS CARCINOGENESIS; EARLY DIAGNOSIS; GENETICS; MIDDLE AGED; PATHOLOGY; PROCEDURES; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY; YOUNG ADULT;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84941413804     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.06.039     Document Type: Article

References (36)

1. IARC The Globocan Project http://globocan.iarc.fr/2012
2. J.D. Carreon, M.E. Sherman, D. Guillen, D. Solomon, R. Herrero, J. Jeronimo, and et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples Int. J. Gynecol. Pathol. 26 2007 441 446
3. M.H. Stoler, and M. Schiffman Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study JAMA 285 2001 1500 1505
4. A.B. Moscicki, M. Schiffman, S. Kjaer, and L.L. Villa Chapter 5: updating the natural history of HPV and anogenital cancer Vaccine 24 Suppl. 3:S3 2006 42 51
5. A. Schneider, H. Hoyer, B. Lotz, S. Leistritza, R. Kuhne-Heid, I. Nindl, and et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy Int. J. Cancer 89 2000 529 534
6. A.M. Priebe 2012 cervical cancer screening guidelines and the future role of HPV testing Clin. Obstet. Gynecol. 56 2013 44 50
7. J. Berkhof, V.M. Coupe, J.A. Bogaards, F.J. van Kemenade, T.J. Helmerhorst, P.J. Snijders, and et al. The health and economic effects of HPV DNA screening in The Netherlands Int. J. Cancer 127 2010 2147 2158
8. J. Dillner Primary human papillomavirus testing in organized cervical screening Curr. Opin. Obstet. Gynecol. 25 2013 11 16
9. N.W. Bulkmans, J. Berkhof, L. Rozendaal, F.J. van Kemenade, A.J. Boeke, S. Bulk, and et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial Lancet 370 2007 1764 1772
10. M. Arbyn, G. Ronco, C.J. Meijer, and P. Naucler Trials comparing cytology with human papillomavirus screening Lancet Oncol. 10 2009 935 936
11. A. Anttila, L. Kotaniemi-Talonen, M. Leinonen, M. Hakama, P. Laurila, J. Tarkkanen, and et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme BMJ 340 2010 c1804
12. G. Ronco, S. Brezzi, F. Carozzi, P. Dalla Palma, P. Giorgi-Rossi, D. Minucci, and et al. The new technologies for cervical cancer screening randomised controlled trial. An overview of results during the first phase of recruitment Gynecol. Oncol. 107 2007 S230 S232
13. M. Arbyn, S. de Sanjose, M. Saraiya, M. Sideri, J. Palefsky, C. Lacey, and et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease Int. J. Cancer 131 2012 1969 1982
14. R. Zappacosta, D. Caraceni, L. Ciccocioppo, T. Rotondo, S. Capanna, D.M. Gatta, and et al. Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme Gynecol. Oncol. 128 2013 427 432
15. T.C. Wright Jr., and M. Schiffman Adding a test for human papillomavirus DNA to cervical-cancer screening N. Engl. J. Med. 348 2003 489 490
16. M. Schmitt, V. Dalstein, T. Waterboer, C. Clavel, L. Gissmann, and M. Pawlita Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns Cancer Res. 70 2010 249 256
17. M. Schmitt, V. Dalstein, T. Waterboer, C. Clavel, L. Gissmann, and M. Pawlita The HPV16 transcriptome in cervical lesions of different grades Mol. Cell. Probes 25 2011 260 265
18. M. Schmitt, and M. Pawlita The HPV transcriptome in HPV16 positive cell lines Mol. Cell. Probes 25 2011 108 113
19. G. Halec, M. Schmitt, B. Dondog, E. Sharkhuu, N. Wentzensen, T. Gheit, and et al. Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer Int. J. Cancer 132 2012 63 71
20. B. Dondog, G.M. Clifford, S. Vaccarella, T. Waterboer, D. Unurjargal, D. Avirmed, and et al. Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study Cancer Epidemiol. Biomark. Prev. 17 2008 1731 1738
21. D. Holzinger, M. Schmitt, G. Dyckhoff, A. Benner, M. Pawlita, and F.X. Bosch Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement Cancer Res. 72 2012 1 11
22. M. Schmitt, B. Dondog, T. Waterboer, and M. Pawlita Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5 + and GP6 + primers J. Clin. Microbiol. 46 2008 1050 1059
23. M. Schmitt, C.E. Depuydt, I. Benoy, J. Bogers, J. Antoine, M. Pawlita, and et al. Viral load of high-risk human papillomaviruses as reliable clinical predictor for the presence of cervical lesions Cancer Epidemiol. Biomark. Prev. 22 2013 406 414
24. F. Castro, W.G. Dirks, S. Fahnrich, A. Hotz-Wagenblatt, M. Pawlita, and M. Schmitt High-throughput SNP-based authentication of human cell lines Int. J. Cancer 132 2012 308 314
25. M. Schmitt, and M. Pawlita High-throughput detection and multiplex identification of cell contaminations Nucleic Acids Res. 37 2009 e119
26. M. Durst, L. Gissmann, H. Ikenberg, and H. zur Hausen A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions Proc. Natl. Acad. Sci. U. S. A. 80 1983 3812 3815
27. J.P. O'Sullivan, R.P. A'Hern, P.A. Chapman, L. Jenkins, R. Smith, A. al-Nafussi, and et al. A case-control study of true-positive versus false-negative cervical smears in women with cervical intraepithelial neoplasia (CIN) III Cytopathology 9 1998 155 161
28. J. van der Marel, W.G. Quint, M. Schiffman, M.M. van de Sandt, R.E. Zuna, S.T. Dunn, and et al. Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological dominance of HPV16 Int. J. Cancer 131 2012 E946 E953
29. S. Vinokurova, and Doeberitz M. von Knebel Differential methylation of the HPV 16 upstream regulatory region during epithelial differentiation and neoplastic transformation PLoS One 6 2011 e24451
30. M.A. Clarke, N. Wentzensen, L. Mirabello, A. Ghosh, S. Wacholder, A. Harari, and et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer Cancer Epidemiol. Biomark. Prev. 21 2012 2125 2137
31. L. Mirabello, C.P. Kratz, S.A. Savage, and M.H. Greene Promoter methylation of candidate genes associated with familial testicular cancer Int. J. Mol. Epidemiol. Genet. 3 2012 213 227
32. J.J. Eijsink, A. Lendvai, V. Deregowski, H.G. Klip, G. Verpooten, L. Dehaspe, and et al. A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients Int. J. Cancer 130 2012 1861 1869
33. A.T. Hesselink, D.A. Heideman, R.D. Steenbergen, V.M. Coupe, R.M. Overmeer, D. Rijkaart, and et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women Clin. Cancer Res. 17 2011 2459 2465
34. L.M. De Strooper, C.J. Meijer, J. Berkhof, A.T. Hesselink, P.J. Snijders, R.D. Steenbergen, and et al. Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions Cancer Prev. Res. 7 2014 1251 1257
35. M. Bierkens, A.T. Hesselink, C.J. Meijer, D.A. Heideman, G.B. Wisman, A.G. van der Zee, and et al. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease Int. J. Cancer 133 2013 1293 1299
36. L. Mirabello, M. Schiffman, A. Ghosh, A.C. Rodriguez, N. Vasiljevic, N. Wentzensen, and et al. Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia Int. J. Cancer 132 2013 1412 1422